



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/38	A1	(11) International Publication Number: WO 00/12517 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19838 (22) International Filing Date: 27 August 1999 (27.08.99) (30) Priority Data: 60/098,313 27 August 1998 (27.08.98) US 60/129,743 16 April 1999 (16.04.99) US 60/144,461 19 July 1999 (19.07.99) US (71) Applicant (for all designated States except BB): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; Basel Street 5, P.O. Box 3190, 49131 Patach-Tiqva (IL). (71) Applicant (for BB only): TEVA PHARMACEUTICALS USA, INC. [US/US]; 1510 Delp Drive, Kulpville, PA 19443 (US). (72) Inventors: FINKELSTEIN, Nina; Katsanelson Street 23, Herzliya (IL). LIDOR-HADAS, Ramy; Mor Street 19, 44242 Kfar Sava (IL). ARONHIME, Judith; Havalutzky Street 9, Rehovot (IL). (74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF		
(57) Abstract New hydrate forms of alendronate sodium, having water content of between about one and about twelve percent, and processes for their manufacture, are disclosed. New crystalline forms of alendronate sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of alendronate sodium are suitable for incorporation into pharmaceutical compositions for combating bone resorption in bone diseases.		